Yesterday, Sept. 10, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $188.49 to $4,934,712.00.

Highlighted Stocks Traded by Insiders:

Carrizo Oil & Gas (CRZO) - FREE Research Report

Ramsey Roger A, who is Director at Carrizo Oil & Gas, sold 1,000 shares at $36.00 on Sept. 10, 2015. Following this transaction, the Director owned 34,850 shares meaning that the stake was reduced by 2.79% with the 1,000-share transaction.

Johnson S P Iv, who is President and CEO at Carrizo Oil & Gas, sold 6,000 shares at $36.22 on Sept. 10, 2015. Following this transaction, the President and CEO owned 613,843 shares meaning that the stake was reduced by 0.97% with the 6,000-share transaction.

The shares most recently traded at $31.92, down $4.30, or 13.46% since the insider transaction. Historical insider transactions for Carrizo Oil & Gas go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 15,500
  • 24-Week # shares sold: 68,289

The average volume for Carrizo Oil & Gas has been 1.3 million shares per day over the past 30 days. Carrizo Oil & Gas has a market cap of $1.8 billion and is part of the basic materials sector and energy industry. Shares are down 18.32% year-to-date as of the close of trading on Thursday.

Carrizo Oil & Gas, Inc., together with its subsidiaries, engages in the exploration, development, and production of oil and gas primarily in the United States. The company has a P/E ratio of 10.8. Currently, there are 17 analysts who rate Carrizo Oil & Gas a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRZO - FREE

TheStreet Quant Ratings

rates Carrizo Oil & Gas as a

hold

. The company's strengths can be seen in multiple areas, such as its expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and weak operating cash flow. Get the full

Carrizo Oil & Gas Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AthenaHealth (ATHN) - FREE Research Report

Stubelis Karl, who is VP and Corporate Controller at AthenaHealth, sold 929 shares at $134.00 on Sept. 10, 2015. Following this transaction, the VP and Corporate Controller owned 0 shares meaning that the stake was reduced by 100% with the 929-share transaction.

The shares most recently traded at $135.24, up $1.24, or 0.92% since the insider transaction. Historical insider transactions for AthenaHealth go as follows:

  • 4-Week # shares sold: 3,915
  • 12-Week # shares sold: 7,415
  • 24-Week # shares sold: 10,530

The average volume for AthenaHealth has been 370,900 shares per day over the past 30 days. AthenaHealth has a market cap of $5.2 billion and is part of the technology sector and computer software & services industry. Shares are down 6.82% year-to-date as of the close of trading on Thursday.

athenahealth, Inc., together with its subsidiaries, operates as a business services company that provides ongoing billing, clinical-related, and other related services to medical group practices and health systems in the United States. The company has a P/E ratio of 674.0. Currently, there are 15 analysts who rate AthenaHealth a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATHN - FREE

TheStreet Quant Ratings

rates AthenaHealth as a

hold

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, robust revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and premium valuation. Get the full

AthenaHealth Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Misonix (MSON) - FREE Research Report

Zaremba Richard A, who is Senior Vice President and CFO at Misonix, sold 600 shares at $11.05 on Sept. 10, 2015. Following this transaction, the Senior Vice President and CFO owned 116,140 shares meaning that the stake was reduced by 0.51% with the 600-share transaction.

The shares most recently traded at $10.25, down $0.80, or 7.8% since the insider transaction. Historical insider transactions for Misonix go as follows:

  • 4-Week # shares bought: 100
  • 4-Week # shares sold: 3,586
  • 12-Week # shares bought: 100
  • 12-Week # shares sold: 3,586
  • 24-Week # shares bought: 100
  • 24-Week # shares sold: 7,086

The average volume for Misonix has been 12,900 shares per day over the past 30 days. Misonix has a market cap of $83.2 million and is part of the health care sector and health services industry. Shares are down 17.22% year-to-date as of the close of trading on Thursday.

Misonix, Inc., a surgical device company, designs, manufactures, and markets therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical applications worldwide. The company has a P/E ratio of 16.3. Currently, there are no analysts who rate Misonix a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSON - FREE

TheStreet Quant Ratings

rates Misonix as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Misonix Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.